RHOA and rheumatoid arthritis: The results showed that inhibiting TAGAP inhibited the expression of NLRP3 and RhoA, which eventually led to a decrease in Th17 cell differentiation and an increase in Treg cell differentiation, and finally improved the severity of RA, thus providing a new experimental foundation for targeting TAGAP as a therapeutic agent for RA (227).